Lee V J, Miller G H, Yagisawa M
Microcide Pharmaceuticals Inc. 850 Maude Avenue, Mountain View, CA 94043, USA. mailto:
Curr Opin Microbiol. 1999 Oct;2(5):475-82. doi: 10.1016/s1369-5274(99)00003-x.
Many advances have recently been made in the development of chemotherapeutic agents for bacterial infections. As a consequence of problematic antimicrobial-resistant bacteria, research is now directed towards narrow-spectrum agents rather than broad-spectrum agents. Further, orally active agents have always been desirable, but today's cost-saving environment, in line with a desire to minimize treatment costs, values reduced administration costs and keeping patients out of the hospital. There has been a recent increase in research into orally active antibacterial agents, such as carbapenems and cephalosporins, and non-glycopeptide natural products.
最近在用于细菌感染的化疗药物开发方面取得了许多进展。由于存在有问题的抗菌耐药细菌，现在的研究方向是窄谱药物而非广谱药物。此外，口服活性药物一直是人们所期望的，而在当今注重节约成本的环境下，出于将治疗成本降至最低的愿望，人们重视降低给药成本并让患者无需住院。最近对口服活性抗菌药物的研究有所增加，如碳青霉烯类和头孢菌素类，以及非糖肽类天然产物。
